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INTRODUCTION
Mucopolysaccharidosis type I (MPS I or Hurler syndrome), a lyso-
somal storage disorder (LSD), is caused by an autosomally recessive 
inherited deficiency of the lysosomal glycosaminoglycan (GAG)-
degrading enzyme α-L-iduronidase (IDUA).1–3 IDUA deficiency leads 
to the lysosomal accumulation of large sugar glycosaminoglycans, 
primarily dermatan sulfate and heparan sulfate. The buildup of 
GAGs results in cellular and metabolic dysfunction and the devel-
opment of organ abnormalities such as the characteristic increase 
in liver size seen in MPS I patients. Pathophysiologically, MPS I is a 
progressive multisystem disorder with multiple organ and tissue 
abnormalities that include skeletal dysplasia, hearing loss, sleep 
apnea, corneal clouding, cardiac manifestations, learning difficul-
ties, and intellectual disability. Without treatment, severe MPS I 
patients will die from cardiorespiratory failure, usually within the 
first 10 years of life.
Current available treatment strategies include hematopoietic 
stem cell (HSC) transplantation (HSCT) and/or enzyme replacement 
therapy (ERT).4–7 HSCT in selected children with severe MPS I can 
increase survival, reduce facial coarseness and hepatosplenomeg-
aly, improve hearing, and maintain normal heart function. HSCT 
may also slow the course of cognitive decline in those patients with 
mild, but not severe, enzyme deficiency. HSCT does not, however, 
improve the skeletal, corneal and central nervous system (CNS) 
manifestations of this disease although recent studies in animal 
models suggest that early intervention may be important in this 
regard.8–11 Enzyme replacement therapy (ERT) can improve liver 
size, growth, joint mobility, breathing, and sleep apnea in those 
with attenuated disease. However, ERT is extremely expensive and 
again fails, like HSCT, to adequately address the critical CNS mani-
festations of MPS I.12
Because SCT has shown benefit when administered peripherally 
(HSCT) or by direct neural stem cell (NSC) transplantation (NSCT) 
into the CNS in experimental models, a logical step is to use mul-
timodal (peripheral and CNS) SCT to address both types of patho-
physiology simultaneously. A long-lived immunodeficient animal 
model of MPS I is thus needed for these preclinical studies.
Current MPS I mouse models based on a NOD/SCID (NS) immuno-
deficient background are short-lived, providing a very narrow win-
dow to assess the long-term efficacy of therapeutic intervention.13 
These NS mice also develop thymic lymphomas, making the assess-
ment of potential tumorigenicity of human stem cell transplanta-
tion problematic.14–17 We therefore developed a new MPS I model 
by breeding MPS I NS mice with the recently developed NOD/SCID/
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Mucopolysaccharidosis type I (MPS I) is an inherited α-L-iduronidase (IDUA, I) deficiency in which glycosaminoglycan (GAG) 
 accumulation causes progressive multisystem organ dysfunction, neurological impairment, and death. Current MPS I mouse 
models, based on a NOD/SCID (NS) background, are short-lived, providing a very narrow window to assess the long-term efficacy of 
 therapeutic interventions. They also develop thymic lymphomas, making the assessment of potential tumorigenicity of human stem 
cell transplantation problematic. We therefore developed a new MPS I model based on a NOD/SCID/Il2rγ (NSG) background. This 
model lives longer than 1 year and is tumor-free during that time. NSG MPS I (NSGI) mice exhibit the typical phenotypic features of 
MPS I including coarsened fur and facial features, reduced/abnormal gait, kyphosis, and corneal clouding. IDUA is undetectable in all 
 tissues examined while GAG levels are dramatically higher in most tissues. NSGI brain shows a significant inflammatory response and 
prominent gliosis. Neurological MPS I manifestations are evidenced by impaired performance in behavioral tests. Human neural and 
hematopoietic stem cells were found to readily engraft, with human cells detectable for at least 1 year posttransplantation. This new 
MPS I model is thus suitable for preclinical testing of novel pluripotent stem cell-based therapy approaches.
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Il2rγ (NSG) mouse.14 This IDUA-deficient mouse on the NSG back-
ground (the NSGI mouse) is longer lived and tumor-free for the time 
period examined. We examined tissue IDUA and GAG accumulation, 
skeletal and corneal abnormalities, tissue pathology, and engraft-
ment of human NSCs and human HSCs in this new MPS I model.
ReSUlTS
Husbandry
Animals that were heterozygous (Het) for IDUA and homozygous 
null for IL2ry became the basis of our breeding scheme to produce 
the NSGI, wild-type (WT) and Het animals used in experiments 
(Supplementary Figure S1). Het matings produce on average six 
to eight pups per litter. To date, of 163 Het matings, 503 pups have 
been produced, 259 of which were female and 244 of which were 
male. Based on the genotype (Supplementary Figure S2) of the 
male pups 25% were WT, 50% were Hets, and 25% were NSGI ani-
mals. Of the female pups, 26% were WT, 47% were Hets, and 27% 
were NSGI animals. Matings between NSGI males and Het females 
or NSGI females and Het males were unproductive. Male and female 
Het and NSGI animals survived at least 1 year; no thymic lympho-
mas were detected in any animals.
Phenotypic features
WT, Het, and NSGI mice all appear identical at birth. By 3–15 weeks 
NSGI mice begin to exhibit phenotypic characteristics of MPS I. NSGI 
mice appear dramatically different from both IDUA Het and WT mice 
as they age. The coarse, rough fur coat of the NSGI mouse is visually 
pronounced (Figure 1). This is in sharp contrast to WT and Het mice 
that appear normal with well-groomed, smooth, white fur coats. The 
facial features and gait of the NSGI animals are also different. NSGI 
animals exhibit a broadening of the head features with less pointed 
nose, smaller ears and deep set eyes (Figure 1). As the NSGI animals 
age, their posture/gait becomes more constrained/pinched and they 
are less ambulatory around the cage when compared with the Het 
and WT counterparts. Indeed, radiographs (Figure 2) show a clear pro-
nounced humped contortion of the NSGI animals’ spines (kyphosis) 
among other skeletal abnormalities. Corneal clouding was also 
grossly visible in the NSGI mice. Corneal examination shows clear cor-
neas for the WT and very cloudy corneas for the NSGI mice (Figure 2). 
Confocal reflectance microscopy shows normal light scattering from 
the corneal nerves in the WT and abnormal light scattering from the 
stromal keratocytes with inclusion bodies in the NSGI mice (Figure 2).
Behavior
Novel object recognition The novel object recognition (NOR) test 
(Supplementary Figures S3–S5) is based on the natural tendency 
of a mouse to explore a novel object rather than a familiar object, 
and can be used to assess impaired cognitive function of transgenic 
mouse models with CNS disorders such as the NSGI mice. NSGI 
mice, along with age- and gender-matched controls, were tested 
for NOR at 6 months of age (Figure 3). The NSGI mice showed a 
significant decrease in exploration, expressed as discrimination 
index (%) (6.0 ± 4.2), compared to Het (27.4 ± 7.7) and WT (32.3 ± 7.0) 
controls (P < 0.05). However, Het and WT mice showed no significant 
difference in exploration when compared to each other. No gender 
differences were seen across the genotypes (data not shown).
Open field Open field analysis (Supplementary Figures S3, S4, and 
S6) was used to assess anxiety levels in NSGI mice compared to WT 
and Het controls. Anxiety and fear is implicated in mice that spend 
most of their time along the periphery of the arena rather than in 
the center of the arena. A one-trial open field test was done at 6 
months of age (Figure 3). The mice were exposed to the same open-
field arena for 10 minutes each and recordings were tracked using 
Ethovision XT9 software (Leesburg, VA). The analysis profile was set 
to express cumulative durations in seconds in which the center-
point of the mouse was in either the “Inner Zone” or the “Outer 
Zone” of the arena. NSGI mice spent significantly less time in the 
“Inner Zone” (27.9 ± 16.1) than either the Het (74.7 ± 25.5) or WT 
(79.3 ± 24.8) mice (P < 0.01). Het and WT mice showed no significant 
difference between each other in time spent in either the “Inner 
Zone” or “Outer Zone (P > 0.05).” No gender differences were seen 
across the genotypes (data not shown).
Figure 1 Gross phenotype of NSGI mice as compared to WT and Het animals. (a) Representative WT mouse at 32 weeks of age. (b) Representative Het 
mouse at 32 weeks of age. (c,d) Two representative NSGI mouse at 32 weeks of age. Note the blunting of facial features in c and the coarseness of hair 
in d. Careful examination of the eyes in d also reveals corneal clouding.
a b
c d
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Rotarod We also performed rotarod trials at 2, 4, and 7 months 
of age (n = 8 for both NSGI and Het at each life stage). At 2 months 
of age there is no difference between the latency to fall for NSGI 
or the Het control group (P > 0.05). In Figure 4a, this is represented 
by the area under the curves centered over the 300–330 second 
interval of the density plots. The performance of the 4 month NGSI 
group not only reveals a statistical difference (P < 0.05) with their 
Het counterparts, but there is also a significant difference (P < 0.05) 
between the 2-month-old NSGI mice and 4-month-old NSGI mice. 
Evidence of the shift in rotarod ability is shown in Figure 4b where a 
shift in area for 4 month NSGI mice is observed while Hets maintain 
an area over 300–330 seconds. There was a further shift for 7-month-
old NSGI mice, with a statistical difference between 4-month-old 
NSGI and 7-month-old NSGI mice (P < 0.001) in addition to the 
difference between 7-month-old Hets and age-matched NSGI mice 
(P < 0.001). Figure 4c shows the complete shift of NSGIs’ ability to 
complete the task compared to their control group.
Tissue IDUA activity and GAG levels
IDUA activity was determined in the heart, liver, brain, kidney, 
lung, skeletal muscle, and spleen of Het and NSGI mice (Table 1). 
As expected, IDUA activity was undetectable in all tissues examined 
from NSGI animals. In contrast, IDUA activity was readily detectable 
in all tissues from Het animals, with variation in activity dependent 
on the tissue under examination. As in previous IDUA tissue deter-
minations of MPS I mouse models,18–20 the highest IDUA activity was 
seen in the spleen and the lowest activity was seen in the brain. 
Significant IDUA activity was also detected in the heart and liver of 
Het animals. GAG concentrations were also measured in the heart, 
liver, brain, kidney, lung, skeletal muscle, and spleen of Het and NSGI 
mice (Table 1). Significant differences were found in all tissues for 
GAG with the exception of muscle GAG. Brain hexosaminidase lev-
els in the NSGI mice were significantly elevated compared to Hets, a 
finding that is similar to that seen in human cases of MPS I.21
Urinary GAG excretion
GAG excretion was measured in the urine of WT (n = 1), Het (n = 
3), and NSGI mice (n = 4). Urinary GAG excretion by NSGI mice was 
consistently higher (fivefold) than that excreted by WT or Het mice 
(Table 1). No significant differences in urinary GAG levels were 
seen between WT and Het animals. The GAG level determined for 
the WT animal of 286 µg GAG/mg creatinine fell within the range 
of 28.4–328 µg GAG/mg creatinine as determined for the Het ani-
mals. In contrast to both WT and Het groups, NSGI animals showed 
Figure 2 CT images of (a) Het (+/−) and (b) NSGI (−/−) mice at 48 weeks 
of age. Notice the contracture of the limbs and the marked kyphosis 
(arrow) in the NSGI mouse. (c–e) Macroscopic photographs of WT (+/+) 
compared to NSGI (−/−) mouse corneas showing clear and transparent 
normal cornea in the WT and severely cloudy corneas in the NSGI mouse 
(arrows). (f,g) Confocal reflectance micrographs of WT (+/+) and NSGI 
(−/−) showing normal light scattering from the stroma and nerves in WT 
cornea compared to marked light scattering from stromal keratocytes 
containing inclusion bodies in the NSGI cornea.
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Figure 3 Open field and novel object recognition testing. (a) Open field 
exploration tested at 6 months of age comparing WT (n = 5), Het (n = 
5), and NSGI (n = 5) mice. Data are expressed as cumulative durations 
in seconds when the center points of the mice are in the “inner zone.” 
Examination of open field center time as a preliminary screen for anxiety-
like behavior reveals a significant genotypic difference between NSGI 
and WT or Het mice. **P < 0.01. (b) NOR memory tested at 6 months 
of age comparing WT (n = 6), Het (n = 6), and NSGI (n = 6) mice. Data 
are expressed as discrimination indices (%). A higher discrimination 
index indicates a preference for the novel object. A significant genotypic 
difference was seen between NSGI and WT or Het mice. **P < 0.01.
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consistently higher urinary GAG levels (n = 3) with determined val-
ues of 811–3,823 µg GAG/mg creatinine.
Blood chemistries
Standard clinical chemistry laboratory metabolic panels were run 
on the blood of NSGI and Het mice (Table 2). The results showed 
significant decreases in albumin, total bilirubin, total protein, and 
triglycerides with a significant increase in creatinine in the NSGI 
mice. The decreases in albumin and total protein could be a sign 
of liver dysfunction while the increase in creatinine could be a sign 
of kidney dysfunction. The decreases in triglycerides and bilirubin, 
on the other hand, suggest malnutrition, which could also account 
for the changes in albumin and total protein. Normal levels of the 
aminotransferases also suggest that liver function is not signifi-
cantly compromised. Interestingly, data from fed animals showed 
that the anion GAP was different between the two groups (data not 
shown). Although there was a trend in sodium, potassium, and chlo-
ride in the fasted animals, the anion gap was not changed.
Brain pathology
The gray matter of WT mice displayed many glial fibrillary acidic pro-
tein (GFAP) immunoreactive protoplasmic astrocytes with numer-
ous thin processes, scattered throughout many brain regions. In the 
primary motor cortex (M1) these astrocytes were mainly present 
in most dorsal and ventral laminae. In marked contrast, intensely 
stained GFAP immunoreactive astrocytes were evident throughout 
Figure 4 Rotarod density plots show the relative likelihood that a mouse, based on age and genotype, will fall at a given time (seconds) versus the 
probability density function (“density”) which is determined by the distribution of the raw data. (a) Hets and NSGI mice at 2 months of age performed 
equally well in the rotarod test (P > 0.05). (b) A slight shift to the left is present for 4-month-old NSGIs indicating poorer performance compared to Hets 
(P < 0.05) and compared to 2-month-old NSGI (P < 0.05) while there is no change in 4-month-old Hets from the 2-month-old Het group (P > 0.05). 
(c) In 7-month-old NSGIs, the time of falling is extremely low (note the large shift to the left) while a large portion of the Het population can still complete 
testing to 330 seconds; the difference is highly significant (P < 0.001). The 7-month-old NSGI mice also performed worse than their 4-month-old 
counterparts (P < 0.001) while 7- and 4-month-old Hets had no statistical difference (P > 0.05). Each group has n = 8.
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the cortex of NSGI mice (Figure 5), and were distributed evenly 
across all laminae. These astrocytes displayed a hypertrophied cell 
body and fewer thickened and intensely stained processes, mor-
phology typical of activated astrocytes. Similar, intensely stained 
and morphologically activated astrocytes were also prominent 
in the thalamus and hippocampus of these NSGI mice (data not 
shown).
A similar pronounced microglial response was evident in the 
brains of NSGI mice, as revealed by intense immunostaining for 
CD68. The distribution of these intensely stained CD68–positive 
microglia closely mirrored that of GFAP staining, being most pro-
nounced in the thalamus and hippocampus (data not shown), and 
within the cortical mantle (Figure 5). Compared to the relatively 
pale CD68 staining of microglia with a small cell body and thin 
processes present in WT animals, the M1 of NSGI mice contained 
many intensely stained CD68 positive cells that were distributed 
evenly across all laminae. These cells displayed a hypertrophied cell 
body, and very few short processes, morphology typical of brain 
macrophages.
Peripheral tissue pathology
Gross examination of peripheral organs (liver, kidney, spleen, 
heart, and skeletal muscle) revealed no obvious or consistent 
findings. However, H&E sections of the liver revealed a clear his-
topathologic abnormality that correlated with genotype—the 
accumulation of “foam cells” (Figure 5e versus 5f ). These foam cells 
were typically found in small to large aggregates, often around 
central veins, but could be found throughout liver parenchyma. 
Toluidine blue stains, which accentuate lysosomes, stained the 
cytoplasm of these cells relatively weakly compared to neighbor-
ing hepatocytes (Figure 5g). Although lacking the typical vesicular 
appearance of macrophages, these cells histologically resembled 
monocyte/macrophage cells, which was confirmed by CD68 
immunostaining (Figure 5h). Potential histopathologic findings in 
the kidney, spleen, heart, and skeletal muscle, which were more 
subtle, are being further assessed.
Human HSC engraftment
Flow cytometric analysis of blood taken from Het and NSGI mice, 
using human- and mouse-specific antibodies against CD45, showed 
that human CD34+ HSCs not only engrafted (Figure 6a–c), but also 
produced identifiable T- and B-cell subpopulations (demonstrated 
by CD3 and CD20, respectively). Ongoing studies are further char-
acterizing HSC engraftment in the NSGI mice as well as the effects of 
HSC engraftment on the course of the disease.
Table 1 IDUA activities, GAG concentrations, and  
hexosaminidase activities in tissues of NSGI and Het mice
Iduronidase activity, (units/mg protein)
Tissue NSGI, N = 10 Het, N = 12 P
Brain 0 1.75 ± 0.248 <0.001
Heart 0 4.84 ± 0.381 <0.001
Kidney 0 2.17 ± 0.481 <0.001
Liver 0 4.89 ± 2.51 <0.001
Lung 0 3.80 ± 0.480 <0.001
Muscle 0 1.47 ± 0.792 <0.001
Spleen 0 18.5 ± 3.88 <0.001
µg GAG/mg dry tissuea
Tissue NSGI, N = 3 Het, N = 4 P
Brain 4.02 ± 0.178 3.53 ± 0.154 0.011
Heart 19.4 ± 2.76 0 <0.001
Kidney 15.7 ± 5.94 0.323 ± 0.645 0.003
Liver 26.6 ± 0.586 0 <0.001
Lung 19.9 ± 2.10 0 <0.001
Muscle 5.98 ± 2.91 0 0.008
Spleen 26.1 ± 6.68 0.805 ± 0.537 <0.001
Urine 1,910 ± 1,660 131 ± 171 0.138
nmol GAG/mg proteinb
Tissue NSGI, N = 7 Het, N = 8 P
Heart 25.7 ± 12.8 8.63 ± 2.20 0.002
Kidney 19.6 ± 6.31 10.2 ± 4.01 0.004
Liver 28.9 ± 9.99 15.2 ± 8.40 0.013
Muscle 17.1 ± 5.27 20.1 ± 7.47 0.401
Hexosaminidase activity, (units/mg protein)
Tissue NSGI, N = 7 Het, N = 8 P
Brain 3,182 ± 258 1,764 ± 446 <0.001
Ns are as listed with the exception of lung and spleen where the Ns are 3 for 
the NSGI and 4 for the Hets.
aUrinary GAG is expressed in µg/mg creatinine. bnmol GAG are approximate 
and are based on the glucuronic acid standard.
Table 2 Blood chemistries from NSGI and Het mice
Analyte NSGI Het P≤
Alanine aminotransferase 264 ± 84 301 ± 232 0.78
Albumin 1.4 ± 0.4 2.6 ± 0.8 0.05
Alkaline phosphatase 40 ± 34 20 ± 1 0.34
Anion gap 20 ± 3 22 ± 4 0.66
Aspartate aminotransferase 1,366 ± 122 609 ± 691 0.36
Calcium 6.3 ± 1.4 6.6 ± 0.9 0.74
Chloride 115 ± 6 108 ± 5 0.12
Creatinine 0.33 ± 0.13 0.13 ± 0.05 0.04
Glucose 119 ± 33 166 ± 118 0.50
Magnesium 2.1 ± 0.4 2.4 ± 0.1 0.25
Phosphorus 9.2 ± 1.6 9.6 ± 0.7 0.67
Potassium 8.7 ± 1.2 11.3 ± 2.4 0.12
Sodium 142 ± 10 130 ± 10 0.15
Total Bilirubin 0.65 ± 0.53 3.1 ± 1.2 0.02
Total CO2 14.8 ± 4.3 10.5 ± 2.6 0.16
Total Protein 3.0 ± 0.9 5.2 ± 1.4 0.05
Triglycerides 27 ± 2.7 72 ± 18 0.01
Urea 25 ± 7.8 18 ± 5.2 0.21
P values (N = 4 for each group) determined by a two-tailed t-test on data 
with differing distributions. Analytes showing a statistical difference 
between the two groups are italicized.
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Human NSC engraftment
Intracerebroventricular injection of human NSCs gave rise to robust 
and widespread engraftment (Figure 6d,e). While human cells could 
be seen widely distributed throughout the cortex, a concentration of 
human cells was seen in the neurogenic zone of the dentate gyrus, as 
has been previously reported. Abundant human cells could be seen 
for at least a year without immunosuppression. Ongoing studies are 
further characterizing NSC engraftment in the NSGI mice as well as 
the effects of NSC engraftment on the course of the disease.
DISCUSSION
We have described a novel immune-deficient mouse model of MPS 
I that survives at least 1 year without the development of thymic 
lymphomas allowing us to test new SCT strategies for MPS I. Our 
ultimate goal is to arrive at a clinical therapeutic approach that 
addresses CNS as well as non-CNS pathologies in the context of 
appropriate immune system considerations.22,23 These bottle-
necks—whole body therapy for a whole body disease and immune-
matching for SCT—are critical and must be addressed before a 
rational clinical SCT for such LSDs can be devised. Because immune 
system considerations are paramount for these studies, we chose 
to derive a modified animal model that is based on the NSG mouse. 
This model faithfully reproduces the CNS and non-CNS pathologies 
seen in patients with MPS I24,25; CNS and non-CNS pathologies are 
clear and easily quantifiable. Importantly, the NSG mouse offers 
two significant advantages over existing immune-deficient mouse 
models: markedly enhanced engraftment after HSCT and longer life 
span without tumor production.14,26 Thus, the NSGI model of MPS I 
allows for a much more thorough evaluation of the effects of SCT 
by allowing the establishment of a human immune system compo-
nent, upon which the eventual clinical trials will be based, and by 
providing a model of sufficient longevity to allow careful evaluation 
of not only efficacy but also possible detrimental effects, especially 
tumor formation.
NSGI mice exhibit the phenotypic features of MPS I including 
coarsened fur and facial features, reduced/abnormal gait, kyphosis, 
and corneal clouding. IDUA was undetectable in all tissues exam-
ined while GAG levels were dramatically higher in most tissues. In 
addition to somatic manifestations of disease, MPS I mice exhibit a 
progressive neurological disorder and widespread neuropathologi-
cal changes, including the accumulation of GAGs and pronounced 
neuroinflammatory changes.18,27 To investigate whether NSGI mice 
displayed a similar phenotype, we immunohistochemically stained 
brain sections from these mice for GFAP as a marker of astrocyto-
sis, and CD68 as a marker of microglial activation. The brain showed 
a significant inflammatory response and prominent gliosis, and 
behavioral tests reveal neurological impairment in NSGI mice. Taken 
together, these data suggest that NSGI mice display a similar robust 
activation of both astrocytes and microglia, similar to that seen in 
previous mouse models of MPS I as well as in human cases of MPS I.
Importantly, we have demonstrated that all three behavioral 
tests can reliably distinguish between Het and NSGI mice, in con-
trast to what has been previously reported.28 The NOR and open 
field tests can discriminate between the two groups as early as 1 
month of age (data not shown) while the rotarod test better shows 
the progression of the disease with age. These robust assays will be 
very useful in determining success of treatments that aim to alle-
viate symptoms or even cure MPS I. This new model, therefore, is 
suitable for preclinical testing of combination stem cell therapies 
aimed at providing multimodal (peripheral and CNS) treatment for 
LSDs such as MPS I and provides a platform to move novel stem cell 
therapies toward Phase 1 clinical trials. Importantly, this platform 
should also provide a testing ground for immune-system matching 
using induced pluripotent stem cell derivatives. Human NSCs and 
HSCs readily engraft in this model and human cells are detectable 
for at least 1 year posttransplantation. Although the intrahepatic 
route for transplantation is not a clinically translatable approach, it 
is technically easier and has been previously reported,29 and serves 
as proof-of-principle.
The immune system considerations for SCT in single gene defects 
extend beyond simple cell rejection. For example, in an immune-
competent, knock-out mouse model of the LSD Sandhoff disease, 
we showed that a single bilateral intracerebroventricular injection 
of NSCs significantly prolonged life-span and delayed the onset of 
the loss of motor skills.30 The animals, however, still died prematurely 
Figure 5 NSGI mice display pronounced cortical glial activation. 
Immunohistochemical staining for markers of (a,b) microglial 
activation (CD68) or (c,d) astrocytosis (glial fibrillary acidic, GFAP) reveal 
pronounced changes in the primary motor cortex of (b,d) NSGI mice, 
compared to (a,c) WT controls. For both markers, NSGI mice displayed 
much darker and intense GFAP and CD68 immunoreactivity than their 
WT counterparts, with (b) enlarged and swollen microglia exhibiting 
a brain macrophage morphology, and (d) intensely stained astrocytes 
appearing hypertrophied with numerous thickened processes. Scale bar 
= 200 µm. (e,f) Liver histopathology shows collections of “foam” cells in 
the liver of NSGI mice, but not in wild-type controls. (e) H&E staining of 
WT liver; (f) H&E staining of NSGI liver showing foam cells; (g) Toluidine 
blue staining of NSGI liver showing a relative lack of staining in foam cells 
compared to adjacent hepatocytes; (h) CD68 immunostaining (brown) 
of NSGI liver showing staining of the foam cells with this monocyte/
macrophage marker. Scale bar: 100 µm.
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of unknown causes. Two of the more likely causes were loss of the 
transplanted cells (either by immune rejection or migration out of 
the CNS) or immune-mediated neutralization of the enzyme pro-
vided by the transplanted cells but lacking in the host cells.31 As 
we could still demonstrate the presence of the transplanted cells 
when the animals died, there appeared to be a lack of tolerance 
to the newly introduced enzyme. The time scale of animal survival 
fits well with production of neutralizing antibodies, and because 
the enzyme is secreted, it is particularly vulnerable to neutralizing 
antibodies produced by the enzyme-naïve immune system. These 
data suggest that a strategy that includes induction of immune tol-
erance, not only to the cells but also to the newly introduced single 
gene product, may be necessary even in cases of CNS-specific dis-
ease and transplantation.
Moreover, unless there is a single source of cells for all stem cells 
transplanted in a multiple stem-cell-type transplantation regimen, 
this regimen will necessarily be a very complicated (and clinically 
untenable) approach. HSCT followed by NSCT, with both cell types 
derived from embryo-derived pluripotent stem cells (ePSCs), is one 
possible approach, but this approach is not yet considered tenable 
since human engraftment of HSCs derived from human ePSCs has not 
been demonstrated (or attempted). Induction of immune tolerance, 
prior to NSCT, with cells derived from ePSCs is another similar possi-
bility but, again, this has not yet been attempted (even then HSCT will 
still be necessary to treat non-CNS pathologies). An approach involv-
ing the use of NSCs differentiated from induced pluripotent stem cells 
(iPSCs) derived from the HSC donor may be a viable alternative given 
that robust NSC differentiation methods exists and that new, noninte-
grative techniques for deriving iPSCs have now been devised. These 
experiments are currently underway in our laboratory.
MATeRIAlS AND MeTHODS
Production of the NSGI mouse
Nonobese diabetic (N) mice homozygous mutant for the catalytic sub-
unit of a nuclear DNA-dependent serine/threonine protein kinase (Prkdc), 
which gives rise to severe combined immunodeficiency (SCID, S), and Het 
for α-L-iduronidase deficiency (IDUA, I) were originally generated for us by 
the Jackson Laboratory (Bar Harbor, ME) following matings of NOD.CB17-
Prkdcscid/J mice with NOD.129(B6)-PrkdcscidIduatm1Clk/J mice.18 These NSI ani-
mals were found, unfortunately, to succumb to thymic lymphomas at ~6–7 
months of age, precluding them from long-term assessments of stem cell 
transplantation strategies. We, therefore, introduced the interleukin-2 recep-
tor, gamma chain (Il2rγ) null (G) background into our NSI animals by crossing 
female NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice with NSI Het IDUA males 
(Supplementary Figure S1). From this colony, the animals homozygous for 
all four mutations were derived (NSG IDUA−/−, NSGI). Control animals—WT 
(IDUA +/+) or Het (IDUA +/−) for the mutant IDUA allele but homozygous for 
NOD-SCID/Il2rγ—were derived from the same cross. Both male and female 
IDUA−/− NSG mice and normal littermates (IDUA +/+, WT, and +/−, Het) 
were used in this study. Animals were housed in sterile cages in HEPA-filtered 
cage racks under a 14:10 hour light:dark cycle and were provided irradiated 
food (Harlan-Teklad 2919, Indianapolis, IN) and sterile deionized water ad 
libitum. To prevent the dams from ignoring or cannibalizing their pups after 
the pups had been manipulated (see below), dams were provided with irra-
diated peanut butter and the cage trays were smeared with small amounts 
of irradiated Vapo-Rub (Procter & Gamble, Cincinnati, OH) for several days 
after manipulation of the pups. All procedures were carried out under an 
approved IACUC protocol from Children’s Hospital of Orange County.
Figure 6 NSGI mice show clear evidence of human hematopoietic stem cell engraftment. (a) Blood mononuclear cells isolated from transplanted mice 
were costained for human-specific and mouse-specific CD45 (hematopoietic specific leukocyte common antigen; hCD45 and mCD45, respectively) 
and showed a robust presence of human cells (circled). Co-staining for (b) hCD45 and CD20 showed the presence of B cells (circled) while costaining 
of (c) hCD45 and CD3 showed the presence of T cells (circled). (d,e) Human neural stem cells engraft widely throughout the NSGI brain. (d) Human 
specific nuclear antigen stained cells in cortex. (e) Human-specific nestin-positive cells (red) in the dentate gyrus of the NSG mouse brain 9 months 
after transplantation. Green GFAP-positive astrocytes are also seen. The scale bars are 25 µm.
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Mouse genotype determination
Mouse genotype was determined with a PCR-based assay for both IDUA 
and Il2rγ (Supplementary Figure S2) using gene-specific primer sets on DNA 
extracted from either mouse tail tips or ear punches at the time of wean-
ing or the day of birth. Briefly, a small piece (1–2 mm) of the tail or ear is 
placed in a PCR tube with 200 µl of 50 mmol/l NaOH and heated to 98 °C for 
1 hour in a PCR thermocycler (Applied Biosystems 2720, Life Technologies, 
Carlsbad, CA). Following reduction of the temperature to 15 °C, 20 µl of a 
1 mol/l Tris–HCl solution, pH 8.0, is added and the sample is spun at 4,000 g 
for 3 minutes. 2 µl aliquots are used as template DNA in a final PCR reaction 
volume of 50 µl.
For IDUA determination, primer pairs oIMR1451 (5’-GGAACTTTGAGACTT 
GGAATGAACCAG-3’ common forward), and oIMR1452 (5’-CATTGTAAATAGG 
GGTATCCTTGAACTC-3’ WT reverse) or oIMR1453 (5’-GGATTGGGAAGACAA 
TAGCAGGCATGCT-3’ mutant reverse) were used in a PCR reaction that 
involved an initial DNA denaturation at 94 °C for 3 minutes, followed by 35 
cycles of denaturation at 94 °C for 30 seconds, primer annealing at 65 °C for 
1 minute and by extension at 72 °C for 1 minute.
For Il2rγ determination, primers oIMR5330 (5’-GTGGGTAGCCAGCTCTT 
CAG-3’ common forward), oIMR5331 (5’-CCTGGAGCTGGACAACAAAT-3’ WT 
reverse) and oIMR5332 (5’-GCCAGAGGCCACTTGTGTAG-3’ mutant reverse) 
were used in a PCR reaction that involved an initial DNA denaturation at 94 
°C for 3 minutes, followed by 35 cycles of denaturation at 94 °C for 30 sec-
onds, primer annealing at 68 °C for 1 minute and by extension at 72 °C for 1 
minute. After a final extension at 72 °C for 2 minutes and cooling to 4 °C all 
PCR products were separated by gel electrophoresis on a 1.5% agarose gel 
containing ethidium bromide prior to visualization with UV light.
Corneal evaluation
Corneal clarity was evaluated in four mice (two WT and two NSGI) and mac-
roscopically documented using a Zeiss Discovery.V12 Stereo Microscope 
(Pleasanton, CA) with attached Nikon D200 digital camera back (Tokyo, 
Japan). Eyes were then enucleated from terminally anesthetized mice, 
placed in cold phosphate buffered saline and mounted on the stage of the 
Zeiss LSM 510 Meta. Confocal reflectance images were obtained using a 40×, 
NA 1.3 Plan-Neofluor Zeiss objective. Images through the entire cornea at 2 
micron steps were collected and representative images were selected.
CT imaging
For whole animal imaging, animals were injected with a lethal dose of 
sodium pentobarbital (250 mg/kg, i.p.). After the disappearance of the toe-
pinch withdrawal reflex, the chest was opened and the animals were trans-
cardially perfused with lactated Ringer’s solution for 20 seconds (150 mm 
Hg) followed by 120 seconds perfusion with fresh 4% paraformaldehyde in 
PBS, pH 7.4.
The computed tomography (CT) system is comprised of a cone beam 
X-ray generator and a flat panel X-ray detector array. Cone beam X-ray pro-
jection images are acquired at up to 512 equally spaced view angles. The 
distance from the center of the reconstruction circle to both the source and 
detector are independently adjustable allowing for a wide range of magni-
fications. For the images presented here, the X-ray tube was operated at 50 
kVp and 0.5 mA. The flat panel sensor had an active area of 12 × 12 cm and 
pixel size of 50 µm (c7942GP, Hamamatsu Photonics, Hamamatsu, Japan). 
Planar images were acquired from 256 projections over 3,600 degree rota-
tion in a step and shoot mode. Trans-axial images were reconstructed using 
a Feldcamp cone beam filtered back projection algorithm. A standard box 
car filter was used.
Behavioral studies
Arena for open field and NOR behaviors. These tests were conducted over a 
3-day period using a custom-made open field arena (27.3 × 27.3 × 20.3 cm) 
composed of clear acrylic walls and base with aluminum supports resting 
on a white polypropylene base (Med Associates, St Albans, VT) The base 
was cut and modified to fit a physical layout of four adjacent chambers to 
measure open field and NOR behavior for four mice simultaneously per 
recording session (Supplementary Figures S3 and S4). An orientating blue 
streak was placed on the front end of the chamber. On the opposite side of 
the blue streak was a partition which allowed the immunodeficient mice 
to be loaded into the chamber while in a laminar flow hood prior to be-
ing moved back by a cart into the behavioral room into its appropriate slot 
on the base with the aluminum supports. When all four mice were placed 
back, the partitions were withdrawn simultaneously and the entire session 
was video-taped. The different genotypes (WT, Het, and NSGI) within the 
experimental mice were sex-matched and age-matched.
NOR. Training and testing methods for NOR memory test were (Supplemen-
tary Figure S5) adopted and modified from the published literature.13,32,33 
Mice were first handled one at a time by placing the mouse on one hand 
while holding onto the tail and letting go only if the mouse was fairly calm 
for 2 minutes/mouse for 2 days. By the second day, the mice were usually 
comfortable sitting on the hand thus allowing 2 mice to be handled at a 
time for 2 minutes. After handling on the second day, the mice were habitu-
ated to the arena for 10 minutes at a time without any objects present. The 
third day was divided into two phases: training (familiarization) and test-
ing (NOR). During the training phase, two identical objects (square tea light 
candle holder 5.08 cm height × 5.08 cm width, filled with hardened cement) 
were placed in the center of the arena equidistant from the walls and each 
other. The mice were loaded into the arena as described above and allowed 
to explore the objects for a total of 10 minutes. After the training session, 
the mice in the chambers were placed back into the laminar flow hood and 
returned to their home-cage for 4 hour retention time before testing. For 
testing, one of the familiar replicates was replaced with a novel object (alu-
minum canister 6.045 cm height × 35.56 cm width × 7.3152 cm diameter, 
filled with hardened cement) and the mice were allowed to explore the 
objects for 5 minutes. The chambers were disinfected as described in the 
Supplementary Materials and objects were sprayed with 70% ethanol and 
allowed to dry overnight in the laminar flow hood.
Exploration was manually scored for cumulative duration (seconds) per 
object and data was used to calculate the discrimination index [DI% = (time 
in novel object zone − time in familiar object zone)/(time in novel object 
zone + time in familiar object zone) × 100]. Exploration was counted when a 
mouse had its nose oriented towards the object (within plane of the object) 
within a distance of 2 cm and/or when the nose was touching the object. 
Exploration was not counted if a mouse was turning around, sitting on top 
and/or climbing over an object. Exploration also was not counted if the 
mouse was looking over the object.
Open field. During the habituation phase on day 2, the session was recorded 
using Noldus Ethovision XT9 software (Wageningen, The Netherlands) to 
track open field behavior (Supplementary Figure S6). Criteria were set to re-
cord four arenas at a time with center-point, nose point, and tail base detec-
tion. Arena settings were designed so that each arena was divided into an 
“outer zone” and a central “inner zone” for exploration. Trial control settings 
were set to initiate tracking 7.0 seconds after playing the recording to allow 
sufficient time to withdraw the partitions. The trial control settings were 
also set to automatically end the trial after a delay of 10.0 minutes after the 
tracking was started. Acquisition settings were set to record the video only 
and complete the tracking later on the recorded video files. After all of the 
trials were recorded, the media files were imported into the corresponding 
Ethovision data file to be tracked. A background image was taken of the 
media files to set and apply the appropriate arena settings and calibrate 
for the size scale of the arena. For detection settings, gray scaling was the 
optimal detection method since there was a good contrast between the 
animal and the background. The range was adjusted as necessary to ensure 
complete tracking of the mice without background noise which could af-
fect the results. All of the tracks were selected for analysis when the mouse 
center-point was either in the “inner zone” or the “outer zone.” The results 
were then automatically calculated with the data expressed as cumulative 
duration (seconds) for each zone and exported to an excel file. The data was 
then analyzed for significant differences in exploration of the “outer zone” 
and “inner zone” across genotypes.
Statistics for open field and NOR. The Dixon q test was first used in R 3.0.0 to 
eliminate any single low or high outlier within the data set at the 95% con-
fidence level. The data was expressed as discrimination index (%) for NOR 
and cumulative duration (s) for open field and was statistically analyzed in 
R using two-way ANOVA for multiple comparisons followed by Tukey’s Post 
Hoc analysis. Data was considered statistically significant when P ≤ 0.05.
Rotarod. A five station rotarod treadmill (Med Associates), housed in a lami-
nar flow hood, was used. The apparatus has five lanes or zones each 5.7 cm 
across with partitions 24.8 cm in diameter to prevent mice from interact-
ing with each other. The suspended beam is 3.2 cm in diameter with rubber 
grooves to provide a suitable grip for the mouse and 16.5 cm high with a 
fixed or accelerating rotational capacity. Each lane has a photobeam placed 
at ground level to record the exact time of the fall.
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Mice were selected according to age and genotype; group sizes varied 
from test to test consisting of anywhere between 2–5 participants. Day 1 
comprised training for the mice. Each mouse was placed in secluded zones 
on an already rotating elevated beam (speed = 4 rpm). Once all the mice had 
established secure footing (not jumping off, not observing the partitions 
and were facing the opposite direction of the rotating beam away from the 
handler) the test would begin at an accelerated rate (4 rpm rising to 40 rpm 
over 300 seconds). The trial was completed once the mouse fell off the beam 
or 300 seconds had passed. The mice were immediately returned to their 
cage after their trial was completed. When all mice had fallen or completed 
300 seconds, a 10 minute resting time was allotted. All times and speeds 
are recorded as well as any pertinent observations made about the mouse’s 
desire to perform or not perform the task at hand. The test was repeated 
three times.
On day 2, trials for the mice were completed. Each mouse was placed in 
a secluded zone on an already rotating elevated beam (speed = 32 rpm). As 
soon as an individual mouse had established secure footing, the test would 
begin at a constant rate of 32 rpm over 330 seconds. The next mouse would 
then be placed in the adjacent zone (this would result in a staggered test-
ing format). Once a mouse had fallen or completed 330 seconds, it would 
be placed immediately back into its cage. Time and speed were recorded as 
well as observations. An intertrial interval of 10 minutes was allowed after all 
mice had completed their test. The test was repeated four times. The aver-
age latency to fall from the rotating beam was calculated using day 2 trials. 
Testing on consecutive days revealed a learning/training ability in both Het 
and NSGI mice that decreased the rotarod’s ability to discriminate between 
the two groups, so a single testing session strategy was employed.
Special attention was given to the disinclination of individual mice to per-
form the rotarod test to criterion on day 2. Mice that held onto the beam 
while it rotated for three consecutive rotations were considered to have 
fallen and the time and speed would be recorded and the mouse would 
be placed back into its cage. Mice that attempted to jump lanes, climbing a 
divider that may or may not have resulted in a fall, for two or more consecu-
tive tests were disqualified, all times were omitted from the overall inter-
pretation and a replacement was selected. “Jumpers” or mice that used the 
walls to lower themselves off of the beam for two or more consecutive tests 
were also disqualified, all data was removed from the pool and a comparable 
replacement was chosen.
Data analysis and statistics for rotarod studies. Density plots were made 
using R 3.0.0 and package ggplot2. The probability density function was 
determined for each condition. The x-axis represents time and the y-axis 
represents the probability differential. Therefore, the area under the curve 
at a specific time interval represents the probability of obtaining that time 
interval from the experiment. The data was also statistically analyzed in R 
using two-way ANOVA for multiple comparisons followed by Tukey’s Post 
Hoc analysis. Data was considered statistically significant when P ≤ 0.05.
Tissue sampling
For analysis of human HSC and NSC engraftment and analysis of tissue GAG, 
IDUA, and hexosaminidase levels, animals were deeply anesthetized with 
isoflurane. After opening the chest and abdomen, blood was drawn directly 
from the heart and processed as described below and urine was drawn 
directly from the bladder and frozen at −80 °C. Subsequently, samples of 
brain, liver, heart, kidney, spleen, and skeletal muscle were taken and frozen 
at −80 °C or immersion-fixed in neutral buffered paraformaldehyde.
Measurement of IDUA and GAGs
Tissues were harvested immediately, frozen on dry ice and stored at −80 
°C until assayed. Frozen tissue samples were thawed and homogenized in 
three volumes of PAD buffer (10 mmol/l sodium phosphate, pH 5.8, 0.002% 
sodium azide, 0.1 mmol/l dithiothreitol) against wet tissue weight. IDUA 
activity was assessed using 250 µmol/l 4-methylumbelliferyl α-L-iduronide 
substrate (4-MUI, Glycosynth, Warrington, Cheshire, UK) as previously 
described,34 except that the incubation temperature was 37 °C and the incu-
bation time was 0.5 hour. Hexosaminidase activity was assessed using 1.25 
mmol/l 4-methylumbelliferyl-N-acetyl-β-D-glucosaminide (EMD Millipore 
Chemicals, Billerica, MA) substrate, incubation time 0.5 hour at a tempera-
ture of 37 °C. Protein concentrations in the extracts were determined by the 
Bradford method using reagents from Bio-Rad Laboratories (Hercules, CA). 
One unit is defined as the activity catalyzing the hydrolysis of 1 nmol sub-
strate in 1 hour. Results were expressed as units per mg of protein.
Urine and tissue GAGs were measured using an Alcian blue dye binding 
method,35 modified as previously published34 or Carbazole Assay.36 Urinary 
creatinine was quantified using the direct endpoint creatinine reagent set 
(Teco Diagnostics, Anaheim, CA) for creatinine and measured by spectro-
photometer at 510 nm on the BioSpec-1601 DNA/protein/enzyme ana-
lyzer (Shimadzu Scientific Instruments, Columbia, MD). Tissue results were 
expressed as µg GAG per mg dry weight of tissue or nmol GAG/mg protein 
and urine results were expressed as µg GAG per mg of creatinine.
Blood chemistries
Mice were fasted for 16–18 hours prior to blood drawing. Whole blood sam-
ples were collected by terminal cardiac blood draw for each mouse using a 
23 g butterfly needle precoated with lithium heparin (Lithium Heparin salt 
from porcine intestinal mucosa; Sigma Aldrich, St. Louis, MO). The blood was 
collected in a BD Microtainer green top tube (Franklin Lakes, NJ) with lithium 
heparin additive and put on ice. Using an adapter, the blood was spun at 
3,000 g for 10 minutes. The samples were processed in a biosafety cabinet 
and serum was carefully pipetted off and put into 1.5 ml screw-top blood 
collection tubes. Serum was then stored at −80 °C until they were analyzed. 
On day of analysis, samples were thawed and delivered immediately to 
CHOC Laboratory Services for analysis. The serum chemistry tests were run 
on a Vitros 5600 instrument from Ortho Clinical Diagnostics.
Histology
For fixed tissues other than brain, dehydrations were done using an auto-
mated processor (Leica TP1020, Leitz-Park Wetzlar, Germany) or manually 
using isopropanol rather than ethanol. (Isopropanol caused less tissue 
shrinkage and brittleness in our hands.) Embedding was performed using an 
embedding station (Leica EG1150). 4–5 um thick microtome sections (Leica 
RM2255) were stained and mounted manually for hematoxylin and eosin, 
toluidine blue, and immunohistochemistry (CD68 antibody) using standard 
and manufacturer protocols.
For brain histology, NSGI and control mice were perfused and tissue pro-
cessed for histology according to established protocols.37–39 Briefly, mice were 
deeply anesthetized with sodium pentobarbitone (1 g/kg) and transcardially 
perfused with phosphate buffered saline (PBS) (Sigma-Aldrich, Poole, UK), 
followed by a freshly made and filtered solution of 4% Paraformaldehyde 
(PFA) in 0.1 mol/l phosphate buffer, pH 7.4. Brains were removed and post-
fixed in 4% PFA at 4 °C for 24 hours, then bisected along the midline. Single 
hemispheres were cryoprotected in 30% sucrose, 0.5% sodium azide in 50 
mmol/l tris buffered saline (TBS), pH 7.6 prior to cutting frozen sections. 40 
µm frozen coronal sections through the rostrocaudal extent of the cortical 
mantle were collected one per well in 96 well plates containing a cryopro-
tective solution (30% ethylene glycol (Sigma-Aldrich), 15% sucrose, 0.05% 
sodium azide in TBS). All subsequent histological analyses were performed 
blind to genotype.
Immunostaining for glial markers. A standard 3,3’-diaminobenzidine tetrahydro-
chloride (DAB) based immunohistochemical protocol was used to assess the 
relative level of glial activation.37,40 Briefly, endogenous peroxidase activity was 
quenched in 1% hydrogen peroxidase (VWR, Radnor, PA) in TBS for 15 minutes. 
Sections were then rinsed in TBS and blocked in 15% normal serum (Vector, 
Northampton, UK) in TBS with 0.3% Triton-X (TBS-T, Sigma-Aldrich), before in-
cubation in the appropriate primary antibody; polyclonal rabbit anti-GFAP (Da-
koCytomation 1:4,000, Ely, UK), rat anti-CD68 (Serotec 1:2,000, Raleigh, NC), in 
10% normal serum in TBS-T overnight at 4 °C. Sections were next rinsed in TBS 
and incubated with the appropriate biotinylated secondary antibodies: swine 
anti-rabbit (DakoCytomation 1:1,000, Carpinteria, CA), rabbit anti-rat (Vector 
1:200) for 2 hours at room temperature. Subsequently, sections were rinsed in 
TBS, followed by incubation in avidin-biotin-peroxidase complex (Vectastain 
Elite ABC kit, Vector, Labs, Burlingame, CA 1:1,000) in TBS for 2 hours and then 
rinsed in TBS. To visualize immunoreactivity, sections were incubated in 0.05% 
DAB (Sigma-Aldrich) containing 0.001% hydrogen peroxide in TBS for up to 25 
minutes, depending on the antigen and then rinsed in ice-cold TBS. Finally, sec-
tions were mounted on gelatin-chrome-coated Superfrost microscope slides 
(VWR), air-dried overnight, cleared in xylene, and coverslipped with DPX (VWR).
Hematopoietic stem cell transplantation
The isolation of HSCs from umbilical cord blood (UCB) and subsequent 
CD34+ HSC isolation was as previously described.41 As the neonatal liver is 
potentially a more efficient site of hematopoietic stem cell development and 
10
MPS I model for stem cell transplantation
DC Mendez et al.
Molecular Therapy — Methods & Clinical Development (2015) 14068 © 2015 The American Society of Gene & Cell Therapy
engraftment and the NSG mouse is more completely NK-deficient, poten-
tially making it a better model for in vivo differentiation of human HSCs, we 
injected CD34+ (0.1–1.0 × 106 cells) human HSCs intrahepatically29 on the 
day of birth into each cryoanesthetized pup. This regimen required no con-
ditioning (radiation or chemotherapy) prior to transplantation. Cells were 
resuspended in 25 µl DPBS per pup to be injected and 25 µl of cell solu-
tion was injected directly into the liver of the unconditioned cryoanesthe-
tized pups, using 31 G × 8 mm BD Ultra-Fine II insulin syringes, as previously 
described.29 Pups were warmed before returning them to their dams.
Neural stem cell transplantation
Human NSCs were isolated from cadaveric postnatal brain cortices and 
grown either as adherent cultures in flasks coated with 10 µg/ml fibronec-
tin or in suspension as neurospheres as previously described41,42 and under 
a CHOC-approved IRB protocol. On the day of birth, pups (and unaffected 
littermate controls) received bilateral intracerebroventricular injections of a 
suspension of NSCs (4–5 × 104 cells/µl in PBS with 0.05% trypan blue) as pre-
viously described30 using a foot-controlled Eppendorf Femto microinjector 
(Hamburg, Germany). The lateral ventricles of cryoanesthetized pups were 
visualized by transillumination of the head; 2 µl of the cellular suspension 
was expelled gently via a glass micropipette inserted transcutaneously into 
each ventricle. After warming them on a sterile warm water bottle, the pups 
were returned to the dams.
Assessment of HSC engraftment by flow cytometry
Quantitation of specific cell surface markers by flow cytometry was done 
to assess HSC engraftment using human-specific and mouse-specific CD45 
antibodies. Costaining with CD3 and CD20 was used to determine if there 
was any T- or B-cell differentiation, respectively, of human HSCs in vivo in 
the mouse.
Assessment of NSC engraftment by immunohistochemistry
Immersion-fixed brains were first cryoprotected by immersion in cold 30% 
sucrose in PBS for 24–48 hours. Cryoprotected brains were embedded and 
frozen at −80 °C in OCT (Ted Pella, Redding, CA) and then mounted, warmed 
to −20 °C and sectioned in a cryostat at 20 µm. Cryostat sections were 
blocked and permeabilized with 3% donkey serum and 0.1% triton X-100 in 
PBS, incubated with primary antibody overnight at 4 °C, and then incubated 
with Alexa 488 goat antirabbit and/or Alexa 594 goat anti-mouse secondary 
antibodies (Molecular probes, Eugene, OR). Cell type-specific antigens were 
detected using antibodies against human-specific nestin or human-specific 
nuclear antigen.
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